Literature DB >> 6147089

Neuroleptic malignant syndrome. Patient with unique clinical and physiologic features.

G P Downey, M Rosenberg, S Caroff, S Beck, H Rosenberg, J C Gerber, T D Heiman-Patterson, M D Aronson.   

Abstract

Lethargy, marked muscle weakness and rigidity, a maximal temperature of 40 degrees C, and a maximal creatine kinase value of 17,240 IU/liter developed in a 36-year-old woman following treatment with several neuroleptics. Initial treatment with dantrolene was unsuccessful. The patient's condition improved gradually over a 10-day period with no specific therapy. Muscle biopsy revealed a contracture pattern diagnostic of malignant hyperthermia susceptibility, as well as abnormal sensitivity to fluphenazine. This report may be the first description of a patient with neuroleptic malignant syndrome in whom muscle biopsy response similar to that seen in malignant hyperthermia occurred and documents that dantrolene is not uniformly successful therapy for this syndrome.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6147089     DOI: 10.1016/0002-9343(84)90716-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  3 in total

1.  Muscle changes in the neuroleptic malignant syndrome.

Authors:  W M Behan; M Madigan; B J Clark; J Goldberg; D R McLellan
Journal:  J Clin Pathol       Date:  2000-03       Impact factor: 3.411

Review 2.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

Review 3.  Cerebellar degeneration in neuroleptic malignant syndrome: neuropathologic findings and review of the literature concerning heat-related nervous system injury.

Authors:  S Lee; A Merriam; T S Kim; M Liebling; D W Dickson; G R Moore
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-03       Impact factor: 10.154

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.